Endocrinology, Vol 134, 658-664, Copyright © 1994 by Endocrine Society

ARTICLES

Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3',5'- monophosphate, estradiol, insulin-like growth factor-I, and serum factors

H Cho, SM Aronica and BS Katzenellenbogen
Department of Physiology and Biophysics, University of Illinois, Urbana 61801.

We have compared regulation of progesterone receptor (PR) gene expression in MCF-7 human breast cancer cells by cAMP and that by estradiol (E2) and insulin-like growth factor-I (IGF-I). Treatment of cells with 8-bromo-cAMP or agents known to activate protein kinase-A, namely cholera toxin plus 3-isobutyl-1-methylxanthine (CT plus IBMX; which increased intracellular cAMP > 10-fold) evoked an increase in PR protein levels as did treatment with IGF-I or E2. Increases in PR caused by IGF-I were not accompanied by increases in PR mRNA, whereas PR mRNA levels were markedly induced by E2 and CT plus IBMX, showing regulation at different levels by these agents. The increases in PR mRNA evoked by E2 or CT plus IBMX were almost completely abolished by treatment with antiestrogen. Treatment with cycloheximide inhibited CT- plus IBMX-mediated PR mRNA stimulation, but not the induction of E2, indicating that the PR mRNA response to cAMP is not a primary one and probably requires de novo protein synthesis. Distinct effects of serum were observed on the expression of PR in MCF-7 cells. PR mRNA and protein were consistently elevated when cells were cultured under low serum conditions (0-0.5% charcoal dextran-treated calf serum) and were reduced as the serum concentration was increased, suggesting that a serum factor(s) repress constitutive PR levels. Also, the ability of CT plus IBMX to stimulate PR declined markedly for cells grown in medium containing higher (5%) serum levels; by contrast, the ability of E2 to induce PR was increased at the higher serum concentration. Thus, unknown serum factors interfere with the action of cAMP in up- regulating PR, whereas serum factors are important for the effectiveness of E2 in stimulating PR. These observations indicate that regulation of PR occurs at different levels by several factors (cAMP, E2, and IGF-I) and imply that cAMP, serum factors, and growth factors, such as IGF-I, in addition to E2 will be of importance in determining PR levels and, hence, cell sensitivity to progestins.

This article has been cited by other articles:

				N. Vasudevan and D. W. Pfaff Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles Endocr. Rev., February 1, 2007; 28(1): 1 - 19. [Abstract] [Full Text] [PDF]

				D. Gallo, C. Ferlini, M. Fabrizi, S. Prislei, and G. Scambia Lack of stimulatory activity of a Phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice Carcinogenesis, July 1, 2006; 27(7): 1404 - 1409. [Abstract] [Full Text] [PDF]

				C. A. Sartorius, D. M.E. Harvell, T. Shen, and K. B. Horwitz Progestins Initiate a Luminal to Myoepithelial Switch in Estrogen-Dependent Human Breast Tumors without Altering Growth Cancer Res., November 1, 2005; 65(21): 9779 - 9788. [Abstract] [Full Text] [PDF]

				C. D. Allred, K. F. Allred, Y. H. Ju, T. S. Goeppinger, D. R. Doerge, and W. G. Helferich Soy processing influences growth of estrogen-dependent breast cancer tumors Carcinogenesis, September 1, 2004; 25(9): 1649 - 1657. [Abstract] [Full Text] [PDF]

				J. Frasor, F. Stossi, J. M. Danes, B. Komm, C. R. Lyttle, and B. S. Katzenellenbogen Selective Estrogen Receptor Modulators: Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells Cancer Res., February 15, 2004; 64(4): 1522 - 1533. [Abstract] [Full Text] [PDF]

				J. Eng-Wong, S. D. Hursting, D. Venzon, S. N. Perkins, and J. A. Zujewski Effect of Raloxifene on Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Leptin in Premenopausal Women at High Risk for Developing Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1468 - 1473. [Abstract] [Full Text] [PDF]

				K. M. Coleman, M. Dutertre, A. El-Gharbawy, B. G. Rowan, N. L. Weigel, and C. L. Smith Mechanistic Differences in the Activation of Estrogen Receptor-alpha (ERalpha )- and ERbeta -dependent Gene Expression by cAMP Signaling Pathway(s) J. Biol. Chem., April 4, 2003; 278(15): 12834 - 12845. [Abstract] [Full Text] [PDF]

				X. Cui, P. Zhang, W. Deng, S. Oesterreich, Y. Lu, G. B. Mills, and A. V. Lee Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer Mol. Endocrinol., April 1, 2003; 17(4): 575 - 588. [Abstract] [Full Text] [PDF]

				L. Labriola, M. Salatino, C. J. Proietti, A. Pecci, O. A. Coso, A. R. Kornblihtt, E. H. Charreau, and P. V. Elizalde Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells Mol. Cell. Biol., February 1, 2003; 23(3): 1095 - 1111. [Abstract] [Full Text]

				J. C. Rowlands, R. Hakkak, M. J. J. Ronis, and T. M. Badger Altered Mammary Gland Differentiation and Progesterone Receptor Expression in Rats Fed Soy and Whey Proteins Toxicol. Sci., November 1, 2002; 70(1): 40 - 45. [Abstract] [Full Text] [PDF]

				Z. Gu, R. Y. Lee, T. C. Skaar, K. B. Bouker, J. N. Welch, J. Lu, A. Liu, Y. Zhu, N. Davis, F. Leonessa, et al. Association of Interferon Regulatory Factor-1, Nucleophosmin, Nuclear Factor-{kappa}B, and Cyclic AMP Response Element Binding with Acquired Resistance to Faslodex (ICI 182,780) Cancer Res., June 1, 2002; 62(12): 3428 - 3437. [Abstract] [Full Text] [PDF]

				A. Makrigiannakis, A.N. Margioris, E. Chatzaki, E. Zoumakis, G.P. Chrousos, and A. Gravanis The decidualizing effect of progesterone may involve direct transcriptional activation of corticotrophin-releasing hormone from human endometrial stromal cells Mol. Hum. Reprod., September 1, 1999; 5(9): 789 - 796. [Abstract] [Full Text] [PDF]

				P. V. N. Bodine, H. A. Harris, and B. S. Komm Suppression of Ligand-Dependent Estrogen Receptor Activity by Bone-Resorbing Cytokines in Human Osteoblasts Endocrinology, June 1, 1999; 140(6): 2439 - 2451. [Abstract] [Full Text]

				A. Revelli, M. Massobrio, and J. Tesarik Nongenomic Actions of Steroid Hormones in Reproductive Tissues Endocr. Rev., February 1, 1998; 19(1): 3 - 17. [Abstract] [Full Text]

				C. L. Bethea and A. A. Widmann Differential Expression of Progestin Receptor Isoforms in the Hypothalamus, Pituitary, and Endometrium of Rhesus Macaques Endocrinology, February 1, 1998; 139(2): 677 - 687. [Abstract] [Full Text] [PDF]

				V. D. H. Ding, D. E. Moller, W. P. Feeney, V. Didolkar, A. M. Nakhla, L. Rhodes, W. Rosner, and R. G. Smith Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway Endocrinology, January 1, 1998; 139(1): 213 - 218. [Abstract] [Full Text] [PDF]

				M. K. K. El-Tanani and C. D. Green Two Separate Mechanisms for Ligand-Independent Activation of the Estrogen Receptor Mol. Endocrinol., June 1, 1997; 11(7): 928 - 937. [Abstract] [Full Text]

				R. S. Piotrowicz, L. Ding, P. Maher, and E. G. Levin Inhibition of Cell Migration by 24-kDa Fibroblast Growth Factor-2 Is Dependent upon the Estrogen Receptor J. Biol. Chem., February 2, 2001; 276(6): 3963 - 3970. [Abstract] [Full Text] [PDF]